Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Fezolinetant in Healthy Chinese Females
NCT04793204Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fezolinetant in vasomotor symptoms, sponsored by Astellas Pharma. Primary endpoints: Number of participants with Adverse Events, Number of participants with laboratory value abnormalities and 13 more. Started Mar 2021; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04793204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793204.